# Merck & Co (MRK) P/E ratio: 144.8× today, 18-year history

URL: https://funkfolio.com/stock/MRK/pe-ratio

> Merck & Co (MRK) P/E ratio is 144.8× today, against 14.5× at the end of fiscal 2025. Its median over 18 fiscal year-ends is 21.6×.

---

## Merck & Co (MRK) P/E ratio

**P/E ratio today:** 144.8× as of Nov 18, 2026, 10:43 AM UTC

Merck & Co (MRK) trades at 144.8× its earnings per share over the last twelve months. At the end of fiscal 2025 (December 31, 2025) its P/E ratio was 14.5×. That is 2.0% lower than the 14.8× of fiscal 2024. Figures as of 18 Nov 2026, 10:43 UTC, from the company's filings with the SEC and Yahoo Finance.

### Key facts

- **P/E ratio today:** 144.8×
- **P/E ratio, fiscal 2025:** 14.5×
- **Change on fiscal 2024:** −2.0%
- **Highest on record:** 128.7× fiscal 2010
- **Lowest on record:** 6.5× fiscal 2009
- **Fiscal years on record:** 18 2007–2025

Figures as of 18 Nov 2026, 10:43 UTC. Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

### Merck & Co P/E ratio, in more detail

Today's figure is 901.6% above the fiscal 2025 year-end.

Across the 18 fiscal year-ends on record (2007–2025), the highest was 128.7× in fiscal 2010 and the lowest 6.5× in fiscal 2009. Today's P/E ratio is above every one of the 18 fiscal year-ends on record; their median is 21.6×.

### P/E ratio at each fiscal year-end

The last point is today's figure; the others are fiscal year-ends.

### Merck & Co P/E ratio, year by year

Merck & Co (MRK) P/E ratio by fiscal year

| Fiscal year | P/E ratio | Change | Year ended | Share price at year-end | Diluted EPS |
| --- | --- | --- | --- | --- | --- |
| Today | 144.8× | — | Nov 18, 2026 | $143.37 | — |
| 2025 | 14.5× | 2.0% down | Dec 31, 2025 | $105.26 | $7.28 |
| 2024 | 14.8× | — | Dec 31, 2024 | $99.48 | $6.74 |
| 2023 | — | — | Dec 31, 2023 | $109.02 | $0.14 |
| 2022 | 19.4× | 30.3% up | Dec 31, 2022 | $110.95 | $5.71 |
| 2021 | 14.9× | 46.9% down | Dec 31, 2021 | $76.64 | $5.14 |
| 2020 | 28.1× | 23.3% up | Dec 31, 2020 | $78.05 | $2.78 |
| 2019 | 22.8× | 30.8% down | Dec 31, 2019 | $86.78 | $3.81 |
| 2018 | 32.9× | 49.1% down | Dec 31, 2018 | $72.91 | $2.21 |
| 2017 | 64.7× | 54.9% up | Dec 31, 2017 | $53.69 | $0.83 |
| 2016 | 41.8× | 23.3% up | Dec 31, 2016 | $56.17 | $1.35 |
| 2015 | 33.9× | 142.7% up | Dec 31, 2015 | $50.40 | $1.49 |
| 2014 | 14.0× | 59.0% down | Dec 31, 2014 | $54.19 | $3.88 |
| 2013 | 34.0× | 66.3% up | Dec 31, 2013 | $47.76 | $1.40 |
| 2012 | 20.5× | 9.7% up | Dec 31, 2012 | $39.06 | $1.91 |
| 2011 | 18.7× | 85.5% down | Dec 31, 2011 | $35.97 | $1.93 |
| 2010 | 128.7× | 1,890.2% up | Dec 31, 2010 | $34.39 | $0.27 |
| 2009 | 6.5× | 22.8% down | Dec 31, 2009 | $34.87 | $5.39 |
| 2008 | 8.4× | 78.5% down | Dec 31, 2008 | $29.01 | $3.46 |
| 2007 | 39.0× | — | Dec 31, 2007 | $55.45 | $1.42 |

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

### How it is calculated

The P/E ratio is the share price divided by earnings per share: for past years this page divides the closing price for the month each fiscal year ended in by that year's diluted earnings per share, and a year with a loss has no P/E.

### How to read it

It is the number of years of current profit the price pays for — a high figure means investors expect growth, and it is best judged against the company's own history.

### P/E ratio at health care companies of similar size

P/E ratio of Merck & Co and comparable companies

| Company | P/E ratio |
| --- | --- |
| [Johnson & Johnson JNJ](https://funkfolio.com/stock/JNJ/pe-ratio) | 42.3× |
| [AbbVie ABBV](https://funkfolio.com/stock/ABBV/pe-ratio) | 50.3× |
| Merck & Co MRK | 144.8× |
| [UnitedHealth Group UNH](https://funkfolio.com/stock/UNH/pe-ratio) | 22.2× |
| [Novartis NVS](https://funkfolio.com/stock/NVS/pe-ratio) | 30.4× |
| [AstraZeneca AZN](https://funkfolio.com/stock/AZN/pe-ratio) | 25.8× |

Price over the last twelve months' earnings per share, as the market data feed reports it.

### Merck & Co, figure by figure

- [Merck & Co market cap](https://funkfolio.com/stock/MRK/market-cap)
- [Merck & Co revenue](https://funkfolio.com/stock/MRK/revenue)
- [Merck & Co earnings](https://funkfolio.com/stock/MRK/earnings)
- [Merck & Co earnings per share (EPS)](https://funkfolio.com/stock/MRK/eps)
- [Merck & Co P/S ratio](https://funkfolio.com/stock/MRK/ps-ratio)
- [Merck & Co P/B ratio](https://funkfolio.com/stock/MRK/pb-ratio)
- [Merck & Co free cash flow](https://funkfolio.com/stock/MRK/free-cash-flow)
- [Merck & Co operating margin](https://funkfolio.com/stock/MRK/operating-margin)
- [Merck & Co dividend](https://funkfolio.com/stock/MRK/dividend)
- [Merck & Co shares outstanding](https://funkfolio.com/stock/MRK/shares-outstanding)
- [Merck & Co total debt](https://funkfolio.com/stock/MRK/total-debt)
- [Merck & Co cash on hand](https://funkfolio.com/stock/MRK/cash)
- [Merck & Co total assets](https://funkfolio.com/stock/MRK/total-assets)
- [Merck & Co return on equity (ROE)](https://funkfolio.com/stock/MRK/roe)
- [Merck & Co return on invested capital (ROIC)](https://funkfolio.com/stock/MRK/roic)

[Merck & Co (MRK) overview: price, valuation and scorecard](https://funkfolio.com/stock/MRK) [All health care companies by market value](https://funkfolio.com/companies/sector/health-care)

### Merck & Co P/E ratio: questions and answers

**What is Merck & Co's P/E ratio?**

Merck & Co (MRK) trades at 144.8× its earnings per share over the last twelve months. At the end of fiscal 2025 (December 31, 2025) its P/E ratio was 14.5×. That is 2.0% lower than the 14.8× of fiscal 2024.

**Is Merck & Co's P/E ratio high or low compared with its own history?**

Today's P/E ratio is above every one of the 18 fiscal year-ends on record; their median is 21.6×.

**What are the highest and lowest P/E ratio figures on record for Merck & Co?**

Across the 18 fiscal year-ends on record (2007–2025), the highest was 128.7× in fiscal 2010 and the lowest 6.5× in fiscal 2009.

**How is Merck & Co's P/E ratio calculated?**

The P/E ratio is the share price divided by earnings per share: for past years this page divides the closing price for the month each fiscal year ended in by that year's diluted earnings per share, and a year with a loss has no P/E. For Merck & Co it is on record here for 18 fiscal years, 2007 to 2025.

Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.

### Learn: P/E ratio

[All stocks guides →](https://funkfolio.com/learn/stocks)

- [P/E ratio explained: what a high or low figure means](https://funkfolio.com/learn/stocks/pe-ratio)

  The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- [PEG ratio: P/E adjusted for growth, and its limits](https://funkfolio.com/learn/stocks/peg-ratio)

  The PEG ratio is a stock's P/E divided by its expected yearly earnings growth in percent. A P/E of 20 with 10% expected growth gives a PEG of 2; with 20% growth, a PEG of 1. A PEG near 1 is the traditional rough mark of a fair price, but the growth figure is a forecast and often wrong.
- [Altman Z-score: formula, zones and where it fails](https://funkfolio.com/learn/stocks/altman-z-score)

  The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.

### Cite this page

Funkfolio, “Merck & Co (MRK) P/E ratio”, data as of 18 November 2026. https://funkfolio.com/stock/MRK/pe-ratio

Underlying data: the company's filings with the SEC and Yahoo Finance.
